Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Vilastobart Monotherapy and Combination Therapy in Advanced Solid Tumors
NCT04896697Phase 2Completed
- Sponsor
- Xilio Therapeutics
- Start
- Sep 2021
- Primary completion
- May 2026
- Modality
- Immune Checkpoint Inhibitors
- Countries
- 1
01
Overview
A Phase 2 trial of vilastobart in solid tumor (advanced stage), colorectal cancer (CRC), sponsored by Xilio Therapeutics. Started Sep 2021; status: completed.
02
Drugs
vilastobart
03
Conditions
solid tumor (advanced stage)colorectal cancer (CRC)
Beyond the preview
Go deeper on NCT04896697.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04896697.